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Abstract The binding of peptides, derived from the model
substrate Suc-Ala-Ala-Pro-Phe-pNA, to the human cyclophilin
hCyp-18 was investigated. HCyp-18 is able to bind 2^4-mer
peptides as well as shorter para-nitroaniline (pNA) derivatives
and pNA surrogates. Although Suc-Ala-Phe-pNA binds hCyp-
18, only proline-containing peptides are able to block efficiently
the peptidyl-prolyl cis/trans isomerase activity. Competition
experiments strongly suggest the existence of two independent
subsites: a S1P ‘proline’ subsite and a S2P^S3P ‘pNA’ subsite.
The interaction at S2’^S3’ requires either a Phe-pNA C-terminus
or a Phe-pNA surrogate bearing an H-bond acceptor able to
bind Trp121 and Arg148 simultaneously. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Immunophilins are a family of ubiquitous proteins which
possess a peptidyl-prolyl cis/trans isomerase (PPIase) activity.
They catalyze the cis/trans interconversion of the amino acyl-
prolyl amide bond in both peptides and proteins [1]. As a
consequence, they accelerate one of the limiting steps of pro-
tein folding and are involved in many related biological pro-
cesses such as cellular multiplication [2] and communication
[3]. The human cyclophilin (hCyp)-18, a cytosolic member of
the cyclophilin subfamily, is also the main receptor of the
cyclic undecapeptide cyclosporine A and is hence implicated
in immunosuppression [4]. Moreover, hCyp-18 has been
shown to play a critical role in the infection of CD4 T-cells
by HIV-1 [5,6] and is an essential constituent of the mature
and infectious virus [7,8]. Therefore, hCyp-18 is an attractive
target for the design of non-immunosuppressive drugs able to
block HIV-1 entry and multiplication [9].
Resolution of several structures of peptide:cyclophilin com-
plexes [10^13] as well as kinetic studies have shown that the
proline residue with the (L) con¢guration is essential for the
PPIase activity [13,14] although it may be replaced with pro-
line isosteres [15]. The in£uence of other residues of the sub-
strate on the interaction is not so critical. HCyp-18 is able to
bind a wide range of substrates including cyclic peptides [16]
and pseudopeptides [17]. The nature of amino acids at P11and
P2 does not in£uence much the second order rate kcat/Km
[19,20] provided that P1 has the (L) con¢guration [13]. The
cyclophilin PPIase activity is also impaired by stereochemistry
at P2P ; (D)-Phe-containing peptides are weak substrates of
hCyp-18 and are unable to compete with the reference sub-
strate Suc-Ala-Ala-Pro-Arg-pNA (4-nitroaniline) [13]. In turn,
the N-terminal part of model substrate tetrapeptides Suc-Ala-
Xaa-Pro-Phe-pNA protrudes outside the catalytic site [11] and
a¡ects neither the a⁄nity nor the activity [13].
The e¡ect of peptide-length and C-terminus on the biolog-
ical activity of model peptides is not well documented. Reso-
lution of structures of dipeptides Xaa-Pro (Xaa is Gly, Ala,
Ser, His) complexed with hCyp-18 shows that the interactions
pattern is di¡erent from those observed with larger peptides.
This suggests that peptides are able to interact in di¡erent
ways with the catalytic site [12].
The design of novel inhibitors of hCyp-18, in particular
substrate analogues, necessitates a delineation of the most
important interactions which in£uence the binding of peptides
to the catalytic pocket. In order to determine the functional
signi¢cance of the interactions revealed by resolution of di¡er-
ent structures, we investigated the in£uence of the length of
peptides derived from the model substrate Suc-Ala-Ala-Pro-
Phe-pNA on their binding to hCyp-18. The a⁄nity of the
peptides for the enzyme was correlated to their ability to in-
hibit the PPIase activity. We also explored the in£uence of the
C-terminus of peptides on both a⁄nity and activity. For this
purpose, succinyl (Suc) or acetyl (Ac) peptides bearing various
substituted aniline (An) moieties were synthesized. In partic-
ular, we studied the interaction of hCyp-18 with carboxy and
amino derivatives of anilide peptides (Fig. 1). We also inves-
tigated the e¡ect of the replacement of the (L)-Phe-pNA motif
with protease-resistant patterns. The in£uence of (D)-Phe and
reduced derivatives on the PPIase activity was prospected as
well.
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2. Materials and methods
2.1. Materials
All the reagents employed were of analytical grade and were pur-
chased from Aldrich Chemical Co. or Sigma. Amino acids and cou-
pling reagents were from Novabiochem, Bachem or Sigma. Substrate
peptides were obtained from Bachem. Trypsin and K-chymotrypsin
were from Sigma. Recombinant hCyp-18 was prepared as described
previously [9].
2.2. Synthesis of peptides and pseudopeptides
Peptide 9 was synthesized by manual solid-phase peptide synthesis
on a rink-amide resin (Novabiochem, 0.47 mmol g31) using four
equivalents of dicyclohexyl carbodiimide (DCC), N-hydroxybenzotria-
zole (HOBT) and diisopropylethylamine (DIPEA) in dry N-methyl-
pyrolidone. The peptide was cleaved from the resin using a mixture of
tri£uoroacetic acid (TFA):triisopropylsilane:water 95:2.5:2.5 and pu-
ri¢ed by RP-HPLC (high performance liquid chromatography) using
a C18 Vydac semipreparative column and a linear gradient of 0.1%
TFA in water:acetonitrile 25:75 to 75:25 in 30 min (£ow rate: 4 ml
min31).
Other peptides were synthesized in solution using standard meth-
ods. Phenylalanine-aninilide derivatives were synthesized by the asym-
metric anhydride method as previously reported [21]. Other couplings
were performed in dichloromethane (DCM) using 1.5 equivalent of
DCC, one equivalent of HOBT and three equivalents of DIPEA (after
neutralization of residual acid used in the deprotection step). Anilide-
containing peptides were deprotected with 4.0 N hydrogen chloride in
dioxane at 0‡C. Other peptides were deprotected with a 50:50 mixture
of TFA in DCM at room temperature. Acetylation and succinylation
were achieved by treatment of the deprotected peptide with respec-
tively two equivalents of acetic anhydride or succinic anhydride, and
four equivalents of DIPEA in acetonitrile. Peptide 13 was obtained by
saponi¢cation of methyl ester 9 with lithium hydroxide in methanol:
water 50:50. Reduction of peptide 3 yielded the para-aminoaniline
derivative 14. The corresponding aryltrimethylammonium could not
be obtained in the Suc series. Reduction of the Ac tripeptide Ac-Ala-
Pro-Phe-pNA 12, followed by permethylation using a large excess of
iodomethane and pentamethylpiperidine [22], gave compound 16.
Peptide 18 was prepared according to Schultz and coworkers [17].
All protected intermediates were puri¢ed by £ash chromatography
on 40^60 Wm (230^400 mesh) Merck silica gel. Peptides were puri¢ed
by RP-HPLC as described above. All compounds were characterized
by 1H- and 13C-nuclear magnetic resonance spectroscopy and ESPMS
(positive or negative ionization). The purity of all compounds was
checked by thin-layer chromatography and RP-HPLC.
2.3. Enzymatic assays
The PPIase uncoupled assay [23] and the PPIase K-chymotrypsin-
coupled assay were carried out in a 35 mM HEPES bu¡er, pH 7.8, at
10 þ 0.5‡C as previously described [24]. The PPIase trypsin-coupled
assay was done in a 35 mM HEPES bu¡er, pH 8.6, at 10 þ 0.5‡C
[25]. Data were processed according to the literature [9].
2.4. Fluorimetric titration
2.4.1. Determination of Kd . Fluorimetric titration was carried out
as previously reported [16].
2.4.2. Competition experiments. Solutions of hCyp-18 (320 nM) in
a 35 mM HEPES bu¡er, pH 7.8, containing compounds 2^5 (concen-
tration ¢xed at a value corresponding to 2 Kd) in dimethylsulfoxide
(DMSO) were incubated 2 min with increasing concentrations of pep-
tide 7 (up to 0.1 M). Fluorescence was monitored as reported above.
80^90% £uorescence quenching was obtained by using a concentra-
tion corresponding to 2 Kd of pNA-containing peptides. Maximum
£uorescence was recorded by incubating hCyp-18 with 10% DMSO
and without pNA compounds.
3. Results
Catalytic e⁄ciency kcat/Km of hCyp-18 for peptide 1 was
determined using the standard uncoupled PPIase assay [23],
whereas kcat/Km for compounds 2 and 3 were obtained with
the K-chymotrypsin-coupled PPIase assay [20,23]. These val-
ues (kcat/Km = 11.8U106 M31 s31 (1) and 7.4U106 M31 s31
(2)) are similar to previously reported data [18,19]. In turn,
peptide 3 was a weaker substrate (kcat/Km = 1.0U106 M31 s31)
than the corresponding tetrapeptide 2. Dipeptide Suc-Pro-
Table 1
Determination of Kd and evaluation of the IC50 of compounds 1^18
Product Kd (WM) þ S.D.a IC50 (WM) þ S.D.b
Suc-Ala-Ala-Pro-Phe-pNA 2 135 þ 20 540 þ 70
Suc-Ala-Pro-Phe-pNA 3 170 þ 40 570 þ 60
Suc-Pro-Phe-pNA 4 180 þ 10 1090 þ 170
Phe-pNA 5 84 þ 4 NIc
pNA 6 350 þ 70 NIc
Ala-Pro 7 d 30 000e
Suc-Ala-Phe-pNA 8 94 þ 7 NIc
Suc-Ala-Ala-Pro-NH2 9 d 14 000e
Suc-Ala-Ala-Pro-Phe-DFA 1 (s 500)f 4400 þ 500
DFA 10 s 100 000 NIc
Suc-Ala-Pro-Phe-An 11 990 þ 60 s 10 000g
Suc-Ala-Pro-Phe-pCMA 12 55 þ 6 700 þ 90
Suc-Ala-Pro-Phe-pCA 13 105 þ 10 s 10 000g
Suc-Ala-Pro-Phe-pAA 14 315 þ 40 5800 þ 400
Ac-Ala-Pro-Phe-pNA 15 140 þ 40 770 þ 200
Ac-Ala-Pro-Phe-pTMAA 16 1450 þ 100 7000 þ 1000
Suc-Ala-Pro-(D)-Phe-pNA 17 95 þ 10 NIc
Suc-Ala-Pro-Phei(CH2-NH)pNA 18 1190 þ 30 NIc
pAA, 4-aminoaniline; pCA, 4-carboxyaniline; pCMA, 4-carboxymethylaniline; pTMAA, 4-(trimethylammonium)aniline; S.D., standard devia-
tion
aDetermined by £uorimetric titration of hCyp-18 Trp121 (Vexcit 285 nm, Vemis 322 nm) at 20‡C in presence of recombinant hCyp-18 (320 nM)
and DMSO (10%) in a 35 mM HEPES bu¡er at pH 7.8 (n = 2).
bDetermined using the standard trypsin-coupled assay in the presence of recombinant hCyp-18 (16 nM), trysine (4.2 WM) in a 35 mM HEPES
bu¡er at pH 8.6 and DMSO (2%) (n = 2).
cNo inhibition was observed at inhibitor concentration up to 100 mM.
dAddition of increasing concentration of peptide did not modify the £uorescence of Trp121.
eEvaluated IC50.
f Compound 1 produces a hCyp-18-independent rise of the £uorescence at high concentration; a plateau was reached at 2 mM.
gEvaluated IC50, 50% inhibition of the PPIase activity was not reached at concentrations up to 10 mM.
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Phe-pNA 4 was resistant to K-chymotrypsin in the standard
conditions. Use of a 10-fold excess of protease showed that
compound 4 is a poor substrate of hCyp-18.
We investigated the e¡ects of peptides derived from the
standard substrate 2 on both the binding to hCyp-18 [16]
and the PPIase activity2[19,23^25]. As expected, ablation of
the N-terminus did not modify signi¢cantly the binding to
hCyp-18 (Table 1). Due to the existence of the speci¢c K-
chymotrypsin cleavage site in peptides 1^4, 8, 11^16, the
IC50 were evaluated using the standard trypsin-coupled
PPIase assay [25] using the substrate Suc-Ala-Ala-Pro-Arg-
pNA. IC50 values were not a¡ected by length changes pro-
vided that peptides possessed a proline residue. Surprisingly,
compounds 5, 6, and 8 devoid of proline were found to be
ligands of cyclophilin. However, these compounds are not
able to block the PPIase activity. In contrast, dipeptide Ala-
Pro 7, which is a ligand of hCyp-18 [10], and Suc-Ala-Ala-
Pro-NH2 9 are weak inhibitors of the cis/trans isomerization
of the substrate peptide Suc-Ala-Ala-Pro-Arg-pNA.
In order to probe the mode of interaction of the di¡erent
pNA-containing compounds, we used tripeptide 9 as a com-
petitor of peptides 2^5 and 8. As anticipated, compound 9
was able to inhibit the PPIase activity (Table 1) without af-
fecting the £uorescence of Trp121. Indeed, peptide 9 is trun-
cated at the C-terminus and hence is not able to quench the
£uorescence of Trp121. Therefore, hCyp-18 was incubated
with concentrations of pNA-containing compounds corre-
sponding to the value of 2 Kd which causes a 80^90% quench-
ing of £uorescence. Recovery of the initial £uorescence of
hCyp-18 Trp121 was obtained by adding increasing concen-
trations of tripeptide 9. As expected Suc-Ala-Ala-Pro-NH2 9
was able to displace proline-containing peptides 2^4. How-
ever, concentrations up to 100 mM in tripeptide 9 did not
restore the £uorescence after preincubation of hCyp-18 with
Phe-pNA 5 or Suc-Ala-Phe-pNA 8 (Fig. 2).
We also investigated the functional signi¢cance of the in-
teraction of Arg148 with the pNA nitro group as revealed by
X-ray crystallography [11]. This was carried out using either
tetrapeptide 1, or tripeptides 11^16 (Table 1). Indeed, deletion
of the ¢rst alanine residue has only a little e¡ect on both the
binding to hCyp-18 and the inhibition of the PPIase activity.
Even though it was a good substrate, peptide 1 was a weaker
ligand of cyclophilin than peptides 2 and 3. 2,4-Di£uoroani-
line (DFA) did not bind hCyp-18. Replacement of pNA with
An caused a signi¢cant decrease of a⁄nity. Substitution of the
nitro group with a H-bond donor such as carboxymethyl
(compound 12) and carboxylate (compound 13) resulted in a
slight improvement of the binding. Replacement with an
amine (peptide 14) had a slightly negative e¡ect on Kd, where-
as introduction of a trimethylammonium induced a 10-fold
decrease of a⁄nity relative to the corresponding nitro com-
pound 153.
We also investigated the ability of these compounds to in-
hibit the PPIase activity. Peptide 12, the best ligand in the
series, e⁄ciently competed with the substrate. All other pep-
tides were very weak inhibitors of the PPIase activity. Unex-
pectedly, pCA-containing peptide 13, which binds hCyp-18
Fig. 1. Chemical structures of various phenylalanyl anilide deriva-
tives used in the present study.
Fig. 2. Competition experiments of various pNA derivatives using
Suc-Ala-Ala-Pro-NH2 9. Recombinant hCyp-18 was preincubated
2 min with 2^8 (dissolved in DMSO) in a 35 mM HEPES bu¡er at
pH 7.8 (n = 2). Increasing concentrations of peptide 9 were added
and hCyp-18 Trp121 was titrated by £uorimetry (n = 2); a : 340 WM
Suc-Ala-Pro-Phe-pNA 3 (IC50 = 8.8 þ 0.4 mM); E : 360 WM Suc-Pro-
Phe-pNA 4 (IC50 = 8.6 þ 0.6 mM); R : 190 WM Suc-Ala-Phe-pNA 8;
b : 170 WM Phe-pNA 5 ; results obtained with tetrapeptide 2
(IC50 = 9.0 þ 0.4 mM) are very similar to those recorded with 270
WM of compound 3 and are not represented for clarity.
2 Although the peptides tested herein are expected to be substrates
rather than inhibitors of the PPIase activity of hCyp-18, the compet-
itive e¡ect relative to the catalyzed isomerization of Suc-Ala-Ala-Pro-
Arg-pNA will be called ‘inhibition’ for conciseness and clarity.
3 Permethylation of the aminoaniline (peptide 13) was carried out
with the Ac-peptide due to synthetic problems encountered with the
Suc derivative. We checked that this N-terminal change had no e¡ect
on the interaction (peptide 12).
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with an a⁄nity equivalent to the reference tripeptide 3, was
not a cyclophilin inhibitor.
Peptide 17 and pseudopeptide 18, which possess respectively
a (D)-Phe residue at P2P and a reduced amide (2-amino-3-
phenyl-propyl)-4-nitroaniline (Phei(CH2-NH)pNA) (Fig. 1),
were assayed as ligands and inhibitors of the hCyp (Table
1). As previously observed by Fischer and coworkers, inver-
sion of the CK con¢guration at P2P caused a complete lack of
inhibition of the PPIase activity [13]. However, this substitu-
tion did not a¡ect the a⁄nity as demonstrated by £uorescence
titration. Reduction of the Phe-pNA carboxyl group (peptide
18) caused a dramatic decrease of a⁄nity and an unexpected
lack of inhibition [17].
4. Discussion
Fig. 3 summarizes the interactions of tetrapeptide 2 with
hCyp-18 as revealed by the X-ray resolution of the complex.
Compilation of structural data of several cyclophilin:peptide
complexes have led to the delineation of peptide moieties
which are important for the interaction. However, only a little
number of data allow to estimate the relative importances of
each interaction for both the binding and the activity of
hCyp-18.
Results showed that ablation of the N-terminal part of
tetrapeptide 2 up to a dipeptide neither a¡ected signi¢cantly
the a⁄nity nor its ability to inhibit hCyp-18. However, reduc-
tion of the length caused a decrease of catalytic e⁄ciency.
These results are consistent with previous studies which
have shown that cis/trans isomerization [26] as well as pro-
teolysis [27] require a minimum binding sequence. Unexpect-
edly, Suc-Ala-Phe-pNA 8 as well as other pNA derivatives
interacted with a good a⁄nity as well. Binding of peptides
devoid of the classical sequence Xaa-Pro-Xaa to a yeast cyclo-
philin [28] and to the trigger factor [29], another important
immunophilin, have been already reported. Interaction of
hCyp-18 with peptides which do not contain proline is well-
known with cyclic peptides [30,31] and linear peptidomimetics
[32^34] as well. However, although peptide 8 and pNA deriv-
atives tightly bind close to Trp121, they are unable to block
the PPIase activity of hCyp-18. The (D)-Phe-containing pep-
tide 17 cannot inhibit cyclophilin [13], whereas it binds the
enzyme with a good a⁄nity. The disconnection between Kd
and IC50 strongly suggests the existence of two functionally
distinct subsites: (i) a S1P proline subsite delineated by Met61,
Ala101, Phe113 and Leu122; (ii) a S2P^S3P Phe-pNA subsite
surrounded by Ile57, Phe60, Trp121 and Arg148 (Fig. 3).
Moreover, this is also supported by our results which demon-
strate that An and di£uoroaniline-containing peptides interact
at the pNA subsite with a relatively low a⁄nity and are weak
inhibitors of the PPIase activity although they contain a pro-
line residue. Competition experiments con¢rm this hypothesis
since tripeptide 9 can compete with peptides 2^4, whereas it is
unable to displace neither Suc-Ala-Phe-pNA 8 nor Phe-pNA
5. This demonstrates the existence of two subsites and implies
that subsites S1P and S2P^S3P are functionally independent. As
a consequence, hCyp-18 can accommodate both S1P- and S2P^
S3P-selective ligands simultaneously. We checked that the
pNA-dependent £uorescence quenching was not the result of
a non-speci¢c interaction with the hydrophobic core de-
lineated by Ile57, Phe60 and Trp121 (Fig. 3). Indeed, hCyp-
18 is able to interact with peptides bearing a hydrophobic C-
terminus such as an amidomethyl coumarin moiety [35,36].
This might be explained by the rotation of the Arg148 side-
chain which enables the binding of hydrophobic molecules
[13,33]. However, no binding of DFA to hCyp-18 could be
detected even at a concentration up to 100 mM although
peptide 1 is a ligand of cyclophilin. Since DFA possesses an
electron-de¢cient phenyl moiety roughly similar to pNA, the
lack of interaction suggests that the H-bond between Arg148
and the nitro group of pNA plays a major role in the binding.
The in£uence of various substituents at the para-position of
An con¢rmed the important role of a H-bond acceptor at this
position. Indeed, hCyp-18 binds more e⁄ciently peptide 12
which has a carboxymethyl C-terminus. On the other hand,
peptides bearing either a charged or an uncharged H-bond
donor have a lower a⁄nity and are weaker inhibitors of the
PPIase activity. Hence, Arg148 seems to play an important
role in the binding of An derivatives and some other com-
pounds such as cyclophilin [37]. However, Arg148 is not im-
plicated in the binding of the Gag polyprotein [38,39].
Structural data of all complexes [10^13] have underlined the
importance of the H-bond between the P2P carbonyl and in-
dole moiety of Trp121. This was also observed with fragments
of the Gag polyprotein [38,39] and cyclophilin [37]. On the
other hand, Schultz and coworkers have demonstrated that a
transition-state analogue of the PPIase activity, bearing a
Phei(CH2-NH)pNA C-terminus, is a good inhibitor of
hCyp-18 [17]. However, we observed that reduction of the
Phe carboxamide (peptide 18) caused a signi¢cant decrease
of the a⁄nity. This indicates that the interaction made by
the P2P carboxamide with Trp121 seems to be critical in
most cases [10,37^39] and cannot be suppressed.
In conclusion, our results show that the speci¢c binding of
peptides to hCyp-18 is not su⁄cient for inhibiting the cis/trans
isomerization of the reference substrate. The N-terminal part
of the peptide can be truncated up to a dipeptide without
signi¢cantly a¡ecting Kd and IC50 values, provided that the
proline residue is maintained at P1P. Cyclophilin is able to
Fig. 3. Main interactions of tetrapeptide 2 with hCyp-18 as revealed
by the X-ray study of the complex [11]. The functionally indepen-
dent subsites S1P and S2P have been delineated from the data ob-
tained in the present study.
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bind smaller ligands and non-proline-containing peptides as
well although they cannot inhibit the PPIase activity. These
results as well as competition experiments strongly suggest the
existence of two functionally independent subsites. The S1P
subsite, encompasses the relatively open catalytic site together
with the narrow proline recognition pocket. The S2P^S3P sub-
site, might control the binding by interacting both with the
guanidinium group of Arg148 and the indole of Trp121. The
nitro group can be replaced with a carboxymethyl group
which is anticipated to make a H-bond with Arg148. The
H-bond between the P2P carbonyl and Trp121 indole seems
to control the interaction at both S1P and S2P^S3P subsites.
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